Lack of prognostic implications of HER‐2/<i>neu</i> abnormalities in 345 stage I nonsmall cell carcinomas (NSCLC) and 207 stage I–III neuroendocrine tumours (NET) of the lung

Abstract excerpt

HER-2/neu oncogene activation by either gene amplification and/or protein overexpression has been documented in several human malignancies. Irrespective of protein overexpression, HER-2/neu gene amplification is rare in lung cancer and studies on its prevalence and clinicopathological implications in early stage non-small cell lung cancer (NCSLC) and neuroendocrine tumours (NET) of the lung are lacking. We...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Cancer Research Studies
• Share to Neuroendocrine Tumor Research Advances
• Share to Peptidase Inhibition and Analysis